dexmedetomidine has been researched along with fluoxetine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chung, HW; Jung, KH; Lee, EJ; Lee, KH; Paik, JY; Park, JW | 1 |
1 review(s) available for dexmedetomidine and fluoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for dexmedetomidine and fluoxetine
| Article | Year |
|---|---|
α2-Adrenergic agonists including xylazine and dexmedetomidine inhibit norepinephrine transporter function in SK-N-SH cells.
Topics: 3-Iodobenzylguanidine; Adrenergic alpha-2 Receptor Agonists; Cell Line, Tumor; Dexmedetomidine; Fluoxetine; Humans; Iodine Radioisotopes; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Receptors, Adrenergic, alpha-2; Xylazine | 2013 |